Form 4: OS Therapies CMO/CSO Granted 500K Stock Options

Robert Petit, Chief Medical Officer and Chief Scientific Officer of OS Therapies Inc., was granted options to purchase 500,000 shares of common stock.

Summary

• Robert Petit, the Chief Medical Officer and Chief Scientific Officer of OS Therapies Inc. (OSTX), was granted options to purchase 500,000 shares of the company's common stock.
• The grant occurred on October 21, 2025.
• These options have an exercise price of $1.8 per share.
• The options will vest in full on October 21, 2026, which is the one-year anniversary of the grant date, contingent on Mr. Petit's continued employment with the issuer.
• The options expire on October 21, 2035.
• Following this transaction, Mr. Petit beneficially owns 200,000 shares of common stock directly and 500,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of a significant number of stock options to a key executive is generally positive as it aligns management's incentives with shareholder interests and promotes long-term retention. The exercise price provides a clear target for stock appreciation.

Positives

• The grant of 500,000 stock options to a key executive, Robert Petit, aligns his long-term interests with those of shareholders.
• The vesting schedule encourages retention of a critical management member.

Risks

• The options' value is contingent on the future stock price of OS Therapies Inc. exceeding the exercise price of $1.8.
• Vesting of the options is dependent on Robert Petit's continued employment with the issuer until October 21, 2026.

Future Outlook

The grant of stock options indicates a long-term incentive for the Chief Medical Officer and Chief Scientific Officer, aligning his future financial interests with the company's performance and shareholder value creation over the next decade, contingent on his continued employment and the company's stock price appreciation.

Management Comments

• Robert Petit is the Chief Medical Officer and Chief Scientific Officer of OS Therapies Incorporated.
• On October 21, 2025, the reporting person was granted options to purchase 500,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement.
• These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on such date.

Industry Context

na

Stakeholder Impact

• Shareholders: The grant aligns executive incentives with shareholder value creation, potentially leading to better long-term performance.
• Employees: The compensation structure for a key executive may set a precedent or reflect the company's overall approach to executive incentives.

Next Steps

• The granted stock options will vest in full on October 21, 2026, subject to Robert Petit's continued employment.
• Robert Petit may exercise the options at any time after vesting and before the expiration date of October 21, 2035.

Key Dates

Keywords

OS Therapies, OSTX, Stock Options, Insider Trading, Form 4, Executive Compensation, Robert Petit, Chief Medical Officer, Chief Scientific Officer, Equity Grant